"San Francisco, CA, USA – December 5, 2013 – Archimedes Inc., a healthcare modeling and analytics company, today announced results of a simulated clinical trial which found that the seven single-nucleotide polymorphisms (7SNP) genetic test for breast cancer was most cost effective when used to guide MRI screenings for patients found to have an intermediate lifetime risk of developing the disease. The study, "Cost-effectiveness of a genetic test for breast cancer risk," appeared in the December 5th online issue of the peer-reviewed journal Cancer Prevention Research.
"This Archimedes Model simulation suggests that genetic screening for breast cancer risk in conjunction with MRI can reduce cancer deaths and identifies a population at an intermediate risk near 20 percent for which it is optimally cost effective," said Tuan Dinh, PhD, vice president of analytics and modeling at Archimedes and one of the authors of study. "This study further illustrates that risk modeling may provide information that will enable physicians to better determine a patient's risk of disease and more appropriately allocate resources that will be beneficial."
In 2007, the American Cancer Society recommended MRI as an adjunct to mammography for the screening of breast cancer in women who have a lifetime risk of breast cancer of approximately 20-25 percent or greater as determined by models based on family history such as the Gail test. In the virtual study, researchers used Archimedes' detailed simulation model of breast cancer risk factors, disease progression, and healthcare processes to estimate the costs and benefits of using genetic testing to refine estimates of risk for purposes of referring women to MRI screening. The simulation included growth, detection, and spread of tumors, as well as screening and treatment.